Project Grant R44CA247353

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Icahn School of Medicine at Mount Sinai aims to develop a novel single-cell multi-omic profiling method called SHARE-ME-SEQ. This method will jointly capture gene expression, chromatin accessibility, and DNA methylation at the single-cell level to provide unprecedented insights into the regulatory mechanisms underlying cancer cell plasticity and metastasis, with a focus on acute myeloid...

This three-year, $4.485 million project grant from the National Institute of Mental Health will develop protocols and workflows for a new imaging approach called Serial-Section Parallel Immunohistochemistry/Fluorescence In Situ Hybridization (SPIFISH). SPIFISH aims to enable highly multiplexed, high-resolution imaging of endogenous molecules in brain tissue. The approach physically subdivides tissue specimens into ultra-thin sections, two orders of magnitude smaller than a neuronal cell body, to...

The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Broad Institute, Inc. to develop a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis." This 3-year project, commencing on August 1, 2024, aims to extend the institute's "Slide-Tags" single-cell spatial genomics technology to enable comprehensive profiling of human tumor samples. The project will integrate molecular, cellular,...

The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Regents of the University of California, San Francisco (UCSF) totaling $679,188. The grant will fund the development of liquid biopsy tests using artificial intelligence-assisted, morphology-based isolation of tumor cells from malignant effusions to evaluate known actionable breast cancer biomarkers and discover new predictive molecular and morphology-based...

The National Cancer Institute (NCI) awarded a $554,653 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Institute for Systems Biology (ISB) to develop "RARECYTEFINDER", a label-free method for the unbiased identification and molecular analysis of rare disseminated tumor cells (DTCs) in liquid and tissue biopsies. The grant aims to create an advanced, genome-wide copy number-based approach to overcome limitations of current DTC detection...

This Project Grant award from the National Human Genome Research Institute (NHGRI), under the Human Genome Research program (CFDA 93.172), provides $383,482 to Electronic Biosciences, Inc. to develop SPINSEQ, an innovative RNA sequencing platform. The goal is to create a highly precise and accurate technology that can detect critical RNA modifications, overcoming limitations of existing RNA sequencing methods. During this Phase I project, the company will focus on developing and optimizing the...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support the development of a novel approach to detect and report on the expression of multiple cytokine genes simultaneously in tissues. The $234,919 award to Yale University, to be completed by August 31, 2027, will combine CRISPR-mediated transcriptional activation with genetically-encoded fluorescent reporters to enable the dynamic, high-sensitivity and multiplexed monitoring of cytokine...

This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) is providing $290,325 to the University of Illinois to develop advanced deep learning methods for estimating cell-type resolution and spatially-resolved gene regulatory networks from spatial transcriptomics data. The objectives are to: 1) Create machine learning models that can integrate regulatory network components and distinguish cell types...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $363,384 to Duke University to develop a suite of computational tools to address key challenges in analyzing in situ spatial transcriptomics data. The project aims to: Develop a framework for optimized cell segmentation that integrates RNA spatial location information with imaging data, using the latest segmentation algorithms. The...

This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) will support the development of a novel spatial proteomics approach to identify immune cell niches within the tumor microenvironment. The $424,734 award, with a project period from December 1, 2024 to November 30, 2026, will be used by the University of Illinois to integrate 3D microscopy techniques with bottom-up proteomic assays. This innovative method aims to provide deep proteome...